tiprankstipranks
Trending News
More News >

Windtree Therapeutics Receives Nasdaq Deficiency Letter

Story Highlights
Windtree Therapeutics Receives Nasdaq Deficiency Letter

Don’t Miss TipRanks’ Half-Year Sale

Windtree Therapeutics ( (WINT) ) has provided an announcement.

On June 18, 2025, Windtree Therapeutics received a deficiency letter from Nasdaq, indicating that the company’s stock price had been below the required $1.00 minimum for 30 consecutive business days. Due to previous reverse stock splits, the company is not eligible for the standard compliance period and must request a hearing by June 25, 2025, to avoid suspension or delisting. The company plans to request this hearing, which will temporarily prevent suspension or delisting while awaiting a decision. However, there is no guarantee that an extension will be granted or that compliance will be regained.

The most recent analyst rating on (WINT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Windtree Therapeutics stock, see the WINT Stock Forecast page.

Spark’s Take on WINT Stock

According to Spark, TipRanks’ AI Analyst, WINT is a Underperform.

Windtree Therapeutics faces significant financial challenges with no revenue and considerable net losses, severely impacting its financial health and stability in the biotechnology sector. The technical analysis suggests bearish momentum, aligning with the weak financials. The negative P/E ratio and lack of dividends make valuation unattractive. Recent corporate events provide a minor positive outlook, but overall, the stock presents considerable risks with limited upside potential without a substantial change in financial performance or market conditions.

To see Spark’s full report on WINT stock, click here.

More about Windtree Therapeutics

Windtree Therapeutics, Inc. operates in the biotechnology industry, focusing on developing novel therapeutics for acute cardiovascular and pulmonary conditions.

Average Trading Volume: 2,751,938

Technical Sentiment Signal: Sell

Current Market Cap: $2.01M

Learn more about WINT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1